SERM-3339
Alternative Names: 3339Latest Information Update: 03 Jul 2002
At a glance
- Originator Aventis
- Class Osteoporosis therapies
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 18 Jun 2002 Discontinued - Phase-II for Postmenopausal osteoporosis prevention in Europe (unspecified route)
- 18 Jun 2002 Discontinued - Phase-II for Postmenopausal osteoporosis treatment in Europe (unspecified route)
- 23 May 2000 Phase-II clinical trials for Postmenopausal osteoporosis prevention in Europe (Unknown route)